IPH-4502

Innate Pharma's IPH6501, a tetraspecific NK cell engager targeting CD20 B cells for Non-Hodgkin Lymphoma, will be featured at the European Hematology Association Congress in June 2025.

Innate Pharma has initiated a Phase 1 clinical trial (NCT06781983) to evaluate the safety and tolerability of IPH4502 in patients with advanced solid tumors expressing Nectin-4.

Innate Pharma SA has announced a comprehensive strategy aimed at driving sustainable growth and innovation in pharmaceutical R&D. Key highlights include the presentation of lacutamab's quality-of-life improvements in CTCL patients, a significant investment for IPH6501 development in follicular lymphoma, and FDA clearance for a new ADC targeting solid tumors.

DATROWAY, a TROP2-directed antibody drug conjugate (ADC), has been approved in the European Union for treating adult patients with unresectable or metastatic HR+/HER2- breast cancer who have received endocrine therapy and at least one line of chemotherapy.

Innate Pharma received FDA clearance for its IND application for IPH4502, an antibody-drug conjugate targeting Nectin-4 in solid tumors.